{"id":534096,"date":"2021-09-02T16:10:16","date_gmt":"2021-09-02T20:10:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mei-pharma-reports-fiscal-year-2021-results-and-operational-highlights\/"},"modified":"2021-09-02T16:10:16","modified_gmt":"2021-09-02T20:10:16","slug":"mei-pharma-reports-fiscal-year-2021-results-and-operational-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mei-pharma-reports-fiscal-year-2021-results-and-operational-highlights\/","title":{"rendered":"MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights"},"content":{"rendered":"
\n

– Reporting of Topline TIDAL Study Data Expected in the Fourth Quarter of Calendar Year 2021 –<\/h2>\n

– MEI Begins Fiscal Year 2022 with $153 Million in Cash –<\/h2>\n

– Conference Call Today at 5:00 p.m. Eastern Time –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Sept. 2, 2021<\/span><\/span> \/PRNewswire\/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2021<\/span>.<\/p>\n

“Fiscal year 2021 was very successful for MEI; it was highlighted by multiple data updates that continue to support the potential of the unique intermittent dosing therapy schedule we designed for zandelisib, both as a monotherapy and in combination with other therapies across a range of B-cell malignances. To that end, we are continuing to expand the clinical program with studies designed to broaden zandelisib’s potential, like the Phase 3 COASTAL study in second line or later follicular lymphoma and the planned start of a Phase 2 study evaluating zandelisib plus venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia,” said\u00a0Daniel P. Gold, Ph.D., president and chief executive officer of\u00a0MEI Pharma. “As we expect to report top-line data from the potentially registrational Phase 2 TIDAL study by the end of the calendar year, we are diligently advancing our pre-commercialization activities, including the building out of our commercial infrastructure, in preparation for the potential commercialization of zandelisib.”<\/p>\n

Dr. Gold\u00a0continued: “In addition to advancing zandelisib clinical development, this past year also brought other exciting pipeline developments supporting new clinical development plans for voruciclib, our oral CDK9 inhibitor, to explore its potential to synergize with KRAS inhibitors, and plans for a Phase 2 study of ME-344 plus bevacizumab evaluating patients with colorectal cancer. We are proud of our progress over the last fiscal year and committed to maintaining our overall focus on the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients.”<\/p>\n

\n Expected Drug Candidate Pipeline Developments\u00a0<\/b>\n <\/p>\n

\n Zandelisib \u2013 Oral PI3K delta inhibitor for the treatment of various B-cell malignancies<\/i>\n <\/p>\n